Drug-resistant microorganisms with a higher fitness--can medicines boost pathogens?
about
Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strainThe trans-kingdom identification of negative regulators of pathogen hypervirulenceNaloxonazine, an Amastigote-Specific Compound, Affects Leishmania Parasites through Modulation of Host-Encoded FunctionsFitness of Leishmania donovani parasites resistant to drug combinationsFitness and Phenotypic Characterization of Miltefosine-Resistant Leishmania majorComparative Fitness of a Parent Leishmania donovani Clinical Isolate and Its Experimentally Derived Paromomycin-Resistant StrainEvolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinentLC-MS metabolomics from study design to data-analysis - using a versatile pathogen as a test case.Transmission potential of antimony-resistant leishmania field isolatesCorrelation between glucose uptake and membrane potential in Leishmania parasites isolated from DCL patients with therapeutic failure: a proof of concept.Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1.Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?Alice in microbes' land: adaptations and counter-adaptations of vector-borne parasitic protozoa and their hosts.Metabolic adaptations of Leishmania donovani in relation to differentiation, drug resistance, and drug pressure.Evaluating drug resistance in visceral leishmaniasis: the challenges.Evaluation of Correlation between the In Vitro Susceptibility of Field Isolates of Leishmania major and Clinical Outcomes of Meglumine Antimoniate Therapy in Fars Province, Iran.Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum.Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum.
P2860
Q24611966-2E8C363F-28A0-4E43-8978-B5BB321743B4Q26782915-66CDE3E1-D7AD-4B75-8BF1-03E90BE0D479Q28468455-766C469A-0004-426C-B397-E92E5FABAA55Q28545794-BC59CA36-EE2C-4D9A-BEE3-C51362E9A8BBQ28546940-8E7EC450-3427-4747-B670-CF0702DAEB1BQ28550306-0B3F0EE6-C36F-4AE0-9F41-7255B2DB8467Q28551055-0E28B34E-09EE-4468-AEBD-7D0FF5C3B344Q30790484-AA46DD60-CCF8-447C-8C14-500B4C8C6CEBQ34299023-7C0B6A2E-EC4B-4109-A87E-54C027BD94DAQ34660710-520BC203-7B72-4AB9-BC38-4034212DF4E8Q36616938-CB13C4BA-AD77-4F20-90C8-3E690C4EF2A4Q38209866-ACCB4D1D-29E6-4B3B-B0DE-D509B58FC118Q38892717-0C88D73D-05E3-4D01-94A8-06BC3F7A9DE6Q38904947-3FD12E53-FE2E-4689-92ED-F856EC0EDE55Q39014583-A7A37381-41B1-495F-B647-F296F2067CC7Q42277296-07640B21-A477-466C-9712-D523708181B3Q42548785-FD707162-3808-448E-9281-F019D6790581Q53120855-9840E559-65E2-46E9-87D4-525EA6E7D4A9
P2860
Drug-resistant microorganisms with a higher fitness--can medicines boost pathogens?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Drug-resistant microorganisms with a higher fitness--can medicines boost pathogens?
@en
type
label
Drug-resistant microorganisms with a higher fitness--can medicines boost pathogens?
@en
prefLabel
Drug-resistant microorganisms with a higher fitness--can medicines boost pathogens?
@en
P2093
P2860
P1476
Drug-resistant microorganisms with a higher fitness--can medicines boost pathogens?
@en
P2093
Jean-Claude Dujardin
Syamal Roy
P2860
P304
P356
10.3109/1040841X.2012.716818
P407
P577
2012-09-06T00:00:00Z